{"id":"cravit-based-sequential-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances (nausea, diarrhea, abdominal discomfort)"},{"rate":null,"effect":"Tendinopathy"},{"rate":null,"effect":"QT prolongation"},{"rate":null,"effect":"Photosensitivity"}]},"_chembl":{"chemblId":"CHEMBL324631","moleculeType":"Small molecule","molecularWeight":"643.29"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a sequential therapy approach for H. pylori eradication that incorporates Cravit (levofloxacin), a broad-spectrum fluoroquinolone antibiotic. Sequential therapy typically involves administering different antibiotic combinations in sequence over a treatment period to improve eradication rates and reduce antibiotic resistance. Levofloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication in H. pylori.","oneSentence":"Cravit-based sequential therapy uses levofloxacin (a fluoroquinolone antibiotic) as part of a multi-drug sequential regimen to eradicate Helicobacter pylori infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:31:26.757Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori infection eradication (sequential therapy regimen)"}]},"trialDetails":[{"nctId":"NCT02466919","phase":"PHASE4","title":"Study of Levofloxacin-based Concomitant Therapy for H. Pylori Eradication in Diabetic Patients","status":"COMPLETED","sponsor":"Chung-Tai Wu","startDate":"2014-05","conditions":"Helicobacter Pylori Infection","enrollment":114},{"nctId":"NCT01537055","phase":"PHASE4","title":"Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2012-02","conditions":"Eradication Rate for Helicobacter","enrollment":600},{"nctId":"NCT00885417","phase":"PHASE4","title":"The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2009-04","conditions":"H. Pylori Infection","enrollment":142}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cravit-based sequential therapy","genericName":"Cravit-based sequential therapy","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cravit-based sequential therapy uses levofloxacin (a fluoroquinolone antibiotic) as part of a multi-drug sequential regimen to eradicate Helicobacter pylori infection. Used for Helicobacter pylori infection eradication (sequential therapy regimen).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}